Date:2/13/2013

ates(35.1)(45.6)Distributions received from equity affiliates—40.0Deferred income taxes and other tax adjustments(90.3)(47.1)Impairment and other asset charges72.8441.1Gains on disposition of assets(5.9)(1.7)Changes in assets and liabilities-Trade receivables(4.1)(43.6)Inventories27.5(61.3)Prepaid expenses and other assets(37.4)(80.5)Trade accounts payable26.5(80.4)Other liabilities183.816.4Other, net8.49.2Net Cash Provided by Operating Activities478.0434.4Cash Flow From Investing Activities:Capital expenditures (including instruments placed with or leased to customers)(290.1)(290.5)Other payments to acquire business(15.0)—Purchases of intangibles and other investments(11.6)(6.9)Proceeds from disposition of businesses and assets12.715.1Net Cash Used in Investing Activities(304.0)(282.3)Cash Flow From Financing Activities:Other borrowings, net(10.7)(2.2)Common stock repurchased—(200.0)Excess tax benefit from stock-based compensation arrangements2.27.5Proceeds from stock options exercised7.947.7Net Cash Used in Financing Activities(0.6)(147.0)Effect of exchange rate changes on cash and cash equivalents1.2(11.9)Net change in cash and cash equivalents174.6(6.8)Cash and cash equivalents at beginning of year597.5604.3Cash and cash equivalents at end of year$
772.1$
597.5Supplemental Cash Flow Information:Cash paid during the year-Interest$
2.2$
2.2Income taxes, net of refunds$
.7$
42.7Hospira, Inc.Net Sales by Product Line(Unaudited)(dollars in millions)Three Months Ended December 31,Years Ended December 31,20122011% Change at

Actual Currency

Rates% Change at

Constant Currency

Rates⁽¹⁾20122011% Change at

Actual Currency

Rates% Change at

Constant Currency

Rates⁽¹⁾Americas--Specialty Injectable Pharmaceuticals

$
539.6$
475.713.4 %13.2 %$
,991.0$
2,000.9(0.5)%0.1 %Medication Management

222.6213.04.5 %4.0 %846.8809
'/>"/>

SOURCE Hospira, Inc. Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
Related medicine technology :

1. Hospira to Present at Upcoming Investor Conferences
2. Hospira and Q Core Medical Sign International Distribution Agreement for Sapphire Infusion System
3. Hospira to Present at the J.P. Morgan 31st Annual Healthcare Conference Jan. 8, 2013
4. Hospira Reports Third-Quarter 2012 Results
5. Hospira to Acquire Active Pharmaceutical Ingredient Manufacturing and R&D Facilities
6. Hospira Reports Second-Quarter 2012 Results
7. Hospira Expands Board of Directors With Election of Dennis M. Fenton
8. Hospira to Host Conference Call for Second-quarter 2012 Results
9. Hospira and Lancaster General Hospital Honored for Patient Safety Initiatives
10. I.V. Clinical Integration Helps Deliver Safety, Efficiency And Financial Benefits; Hospira Shares Snapshot Of Results, Process
11. Hospira to Present at Upcoming Investor Conferences